From the Journals

Cenobamate Shows Stronger Real-World Seizure Control

Large retrospective analysis highlights differences in seizure control, retention, and adverse effects among newer agents

Share

A pooled analysis from the CREW study evaluated the effectiveness of cenobamate compared to brivaracetam, lacosamide, and perampanel in patients aged 16 and older with drug-resistant focal epilepsy. The study, encompassing nearly 2,000 patients across 71 epilepsy centers, revealed that cenobamate significantly increased the odds of achieving a 50% reduction in seizure frequency at both 6 and 12 months. Despite a higher rate of adverse effects, cenobamate maintained long-term retention rates, indicating its effectiveness in a challenging patient population. The findings highlight the need for further real-world studies to guide treatment choices in epilepsy.

Original Source(s)

Cenobamate Shows Stronger Real-World Seizure Control

Large retrospective analysis highlights differences in seizure control, retention, and adverse effects among newer agents

  • by Henry Thomas

  • March 4, 2026

  • 2 min

Related Content

Epilepsy Linked to Heart Risks in Seniors

Brain Cell Networks Mapped with CRISPR

A new Perturb-seq platform utilizes adeno-associated viruses vectors and transposons to examine cell-specific transcriptional networks within the developing brain in vivo.

New Score Assesses Epilepsy Risk Post-CVT

With DIAS3 predicting epilepsy risk post-CVT from as low as 7% to 83% over three years, doctors can tailor ASM strategies based on a patient’s individual profile—advancing precision in CVT care.